|Outcome||Relative effect 95%CI||LoD||Trt. better when||I2||k (RCT/OBS)||Bayesian probability||Overall ROB||Publication bias||Degree of certainty||Endpoint importance||Published MA|
|PCR-negative conversion||0.92 [0.77, 1.09]||> 1||0%||1 study (1/-)||17.3 %||low||not evaluable||high||important||-|
|PCR-negative conversion (7-day)||0.92 [0.77, 1.09]||> 1||0%||1 study (1/-)||17.3 %||low||not evaluable||high||important||-|
|adverse events||1.00 [0.20, 5.07]||< 1||0%||1 study (1/-)||50.0 %||low||not evaluable||high||non important||-|
LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.